Table 3 Reported cases of MEWDS secondary to MFC/PIC lesions that developed into FCE (the first three) and MEWDS occurring concurrently with CNV (the last 6 cases).i.e. d for day, w for week, m for month, y for year, MTX for methotrexate, PDT for photodynamic therapy, IVR for intravitreal ranibizumab, — for none, FCE for focal choroidal excavation. †, Occurrence time of FCE;‡,Location of CNV /interval between CNV&MEWDS
Gender | Age | Eye | Complaints | History | Refactive state | Choroidal thickness | First vision acuity | Last vision acuity | Anterior chamber cells | Vitreous cells | FCE†or CNV‡ | Intervention | Follow-up time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Female | 37 | Right | Blurred vision with scotoma | — | Mild myopia | Increased | 20/200 | 20/25 | — | ++ | 4w | Observation | 12 m |
Female | 25 | Right | Blurred vision | Prodrome of virus infection | Moderate myopia(after refractive surgery ) | Increased | 20/50 | 20/20 | — | — | Recurrent FCE with recurrence three times in 2y | Oral glucocorticoid 1.0 mg/kg for 2w | 24 m |
Female | 40 | Left | Vision loss | Within 1w after a cold | Not mentioned | Increased | 20/32 | 20/16 | — | + | 4w | Oral glucocorticoid 15 mg/day for 2w | 6 m |
Male | 16 | Left | Vision loss | — | — | Not mentioned | 20/40 | 20/25 | — | — | Superonasal side of fovea/1m | Acetazolamide 250 mg for 2w, Bevacizumab 2 mg for 2w, glucocorticoid 100 mg for 3d, 50 mg for 3d. in a total of 2 m | 18 m |
Female | 16 | Left | Obvious vision loss | — | Moderate myopia | Increased | 20/75 | 20/75 | — | Not mentioned | Temporal side of fovea/concurrent | Observation | 20 m |
Female | 29 | Left | Vision loss | Polycystic ovary syndrome | Mild myopia | Increased | 20/150 | 20/60 | — | Not mentioned | Fovea/concurrent | Intravitreal anti-VEGF twelve times | 18 m |
Male | 29 | Right | Vision loss | — | Moderate myopia | Increased | 20/400 | 20/32 | — | Not mentioned | Fovea/concurrent | Observation | 3 m |
Female | 18 | Right | Vision loss | — | — | Increased | 20/200 | 20/20 | — | Not mentioned | Above fovea/concurrent | Oral glucocorticoid 40 mg/day and reduced gradually for 1 m | 1 m |
Male | 22 | Left | Vision loss | Within 2w after a cold | Myopia for 2.5D | Increased | 20/200 | 20/20 | Not mentioned | Not mentioned | Superonasal and inferotemporal side of fovea/concurrent | Observation for 7Â m and Intravitreal anti-VEGF once | 10Â m |